Terrapeutics focuses on discovering novel therapeutic solutions from soil-based microorganisms. Its groundbreaking discovery technology combines synthetic biology, sequencing tools, and computational biology to utilize soil's full potential to discover novel small molecules that can tackle 'undruggable' targets. It does that, by disrupting a natural environment in soil with an engineered microorganism (according to the pre-defined drug target aims to tackle) that threatens that environment. This threat forces its residents to respond by producing small molecules against the drug target we are aiming at. The results show that this technology identifies the specific drug-producing bacteria and the genes associated with such activity with high success rates. The company's lead discovery program focuses on pan KRAS inhibitors, the next generation of solutions for a target that drives 25% of cancers. Through the KRAS discovery program, the company has demonstrated its ability to overcome two critical bottlenecks in soil-based drug discovery – the ability to swiftly identify drug-producing bacteria and the associated biosynthetic gene clusters against a predefined drug target as challenging as it can be. Recent Progress: • Discovered and isolated the first natural pan-KRAS inhibiting molecules from soil bacteria, the second and third discoveries are in their final confirmation stages. • 1st hit compound TRP-001 demonstrates significant potency and superiority over competing molecules that are either commercial or in advanced clinical development • Demonstrated our platform's ability to discover novel drug-like molecules against high-value, "undruggable" targets We're currently backed by Peregrine Ventures, Bristol Myers Squibb, Illumina, and others. This fall, we're heading into a $10M seed round to expand our platform and accelerate multiple discovery programs against pharmaceutical research's most challenging "holy grail" targets.